If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Trading Update

7 Jul 2005 07:01

Torex Retail PLC07 July 2005 7 July 2005 Torex Retail Plc Trading Update Torex Retail Plc ("Torex Retail" or "the Group"), is pleased to announce apositive update on trading for the six months ended 30 June 2005. This reflects a strong organic performance in all areas of the Group, includingnew LUCAS contract wins totalling approximately £10 million. LUCAS • New sales success for LUCAS, the Group's market leading JAVA based electronic point of sale (EPOS) solution, with a number of significant contract wins with major international retailers including Deichmann, Reiss and Esprit and UK based retailers including RD Scott, Co-op Home Stores and Mitsukoshi. In addition, LUCAS has now been installed in over 40 stores and more than 150 lanes in the UK and Ireland, with more planned for the next few months. These installations will now act as excellent reference sites for our large prospect pipeline. PERFORMANCE MANAGEMENT PRODUCTS • Significant new wins for SMARTDECISION, the Group's merchandise planning product, including Ann Taylor in America, Modelo Continente in Portugal (part of the €1.6 billion turnover Sonnae Group) and Littlewoods and Oldrids in the UK. PETROLEUM & CONVENIENCE • A new £3.3 million contract for the Petroleum and Conveniencedivision, to install its market leading PoS solution 'Iridium' and backoffice system 'Prism' into 225 stores across the UK. BUSINESS DEVELOPMENT Alphameric Retail, which was acquired in November 2004, is now fully integratedinto Torex Retail, ahead of schedule. Through RSS, which was acquired in May 2005, we are achieving real momentum andare already making strong progress in gaining greater penetration of the USmarket, the largest market in the world for retail systems. In addition, we are currently working towards finalising the recommended offersfor XN Checkout Holdings plc and Anker plc. Both of these businesses meet withour strategic goal of ultimately becoming a global market leader and inparticular are expected to be earnings enhancing. This statement regardingearnings enhancement does not constitute a profit forecast nor should it beinterpreted to mean that earnings per share of Torex Retail for the current orfuture years will necessarily match or exceed the historical published earningsper share of Torex Retail. INTERIM RESULTS The Board intends to announce results for the six months ended 30 June 2005 inlate September and expects these results to be consistent with full yearmanagement expectations. The Group continues to enjoy a high level of revenuevisibility, based on strong recurring revenues from its blue-chip customer base.This, coupled with its new business pipeline, gives the directors confidenceabout the Group's prospects for 2005 and beyond. Chris Moore, Chief Executive, Torex Retail Plc, comments: "I am delighted with the progress we have made in all areas of our operationsduring the first half of this year. The cyclical upturn in the market is nowgathering momentum, most notably evidenced by our significant new contract winsfor LUCAS. Coupled with this, our accelerated growth plan through acquisitionsis already positioning us such that we are currently in discussions with some ofthe world's largest retailers as potential customers, both in Europe and theUSA. Enquiries: Torex Retail Plc 0870 050 9900 Chris Moore, Chief Executive Richard Thompson, Group Finance Director Citigate Dewe Rogerson 020 7638 9571 Ginny Pulbrook / Seb Hoyle This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th May 201812:12 pmRNSResult of AGM
2nd May 20187:00 amRNSTRX BioSurgery GPO agreement with Premier, Inc.
27th Apr 20187:00 amRNSPosting of Annual Report and Notice of AGM
24th Apr 20187:00 amRNSDermaPure manufacturing at CellRight Facility
19th Apr 20183:29 pmRNSHolding(s) in Company
5th Apr 20187:17 amEQSHardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note
26th Mar 20187:00 amRNSAnnual results for period ended 31 December 2017
16th Mar 20183:40 pmRNSPublication of Financial Results
8th Mar 20187:15 amRNSHardman & Co: Full-year 2017 - what to look for
6th Mar 20187:00 amRNSLong term distribution agreement with Arthrex, Inc
26th Feb 20187:00 amRNSNotice of Results
26th Feb 20187:00 amRNSLaunch of BioSurgery and new distributor agreement
2nd Feb 20187:00 amRNSIssue of Equity
22nd Dec 20179:30 amRNSIssue of Equity
1st Dec 20177:00 amRNSDirectorate Change
1st Dec 20177:00 amRNSIssue of Equity
2nd Nov 20177:00 amRNSAppointment of CEO
18th Oct 20177:00 amRNSDirectorate Change
11th Oct 20177:15 amRNSHardman Research: Dual revenue stream growth
28th Sep 20173:15 pmRNSUnaudited Interim Results
8th Sep 20177:00 amRNSNotice of Results
5th Sep 20173:52 pmRNSNotification Of Major Holdings
30th Aug 20175:15 pmRNSIssue of Equity
16th Aug 201712:22 pmRNSHolding(s) in Company
11th Aug 20173:45 pmRNSHolding(s) in Company
11th Aug 20173:37 pmRNSHolding(s) in Company
10th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20172:45 pmRNSHolding(s) in Company
10th Aug 20171:10 pmRNSHardman Research: CellRight transforming US growth
10th Aug 201710:10 amRNSHolding(s) in Company
9th Aug 20173:00 pmRNSHolding(s) in Company
9th Aug 20172:30 pmRNSDirector/PDMR Shareholding
8th Aug 20171:41 pmRNSResults of General Meeting and Total Voting Rights
21st Jul 20176:00 pmRNSCirc re.CellRight Acquisition
21st Jul 20178:05 amRNSSuccessful fundraising of £40 million
20th Jul 20176:03 pmRNSProposed Acquisition and Placing
30th Jun 201712:00 pmRNSResult of AGM
2nd Jun 20177:00 amRNSAnnual results for period ended 31 December 2016
31st May 201710:46 amRNSPotential Acquisition Update
19th May 201711:35 amRNSPotential Acquisition
3rd Apr 20177:00 amRNSIssue of Equity
13th Mar 20177:10 amRNSHardman Research: Addressing woundcare in the US
1st Mar 20177:00 amRNSInnovative Technology Contract Awarded
2nd Feb 20177:00 amRNSDermaPure® added to the Federal Supply Schedule
6th Jan 20177:00 amRNSDirectorate Change
9th Dec 20167:15 amRNSHardman Research: a/c change: Not simply 11/12ths
7th Dec 20161:04 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Dec 20167:00 amRNSDermaPure secures GPO agreement with Premier, Inc.
28th Nov 20167:05 amRNSOrthoPureT XT update
22nd Nov 20167:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.